Gita V Massey

Summary

Affiliation: Virginia Commonwealth University
Country: USA

Publications

  1. ncbi request reprint Continuous lidocaine infusion for the relief of refractory malignant pain in a terminally ill pediatric cancer patient
    Gita V Massey
    Department of Pediatrics, Division of Hematology Oncology, Children s Medical Center, Medical College of Virginia, Virginia Commonwealth University, Richmond, USA
    J Pediatr Hematol Oncol 24:566-8. 2002
  2. ncbi request reprint Transient leukemia in newborns with Down syndrome
    Gita V Massey
    Department of Pediatrics, VCU Health System, Medical College of Virginia, Richmond, Virginia, USA
    Pediatr Blood Cancer 44:29-32. 2005
  3. ncbi request reprint A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): Children's Oncology Group (COG) study POG-9481
    Gita V Massey
    Virginia Commonwealth University, Medical College of Virginia, PO Box 980121, Richmond, VA 23298, USA
    Blood 107:4606-13. 2006
  4. ncbi request reprint Incidence and treatment of potentially lethal diseases in transient leukemia of Down syndrome: Pediatric Oncology Group Study
    Fawaz Al-Kasim
    Division of Hematology Oncology, The Hospital for Sick Children, Toronto, Ontario, Canada
    J Pediatr Hematol Oncol 24:9-13. 2002
  5. doi request reprint Cardiomyopathy in children with Down syndrome treated for acute myeloid leukemia: a report from the Children's Oncology Group Study POG 9421
    MAUREEN M O'BRIEN
    Division of Pediatric Hematology Oncology, Lucile Packard Children s Hospital, Stanford, CA 94304, USA
    J Clin Oncol 26:414-20. 2008

Collaborators

Detail Information

Publications5

  1. ncbi request reprint Continuous lidocaine infusion for the relief of refractory malignant pain in a terminally ill pediatric cancer patient
    Gita V Massey
    Department of Pediatrics, Division of Hematology Oncology, Children s Medical Center, Medical College of Virginia, Virginia Commonwealth University, Richmond, USA
    J Pediatr Hematol Oncol 24:566-8. 2002
    ..Intravenous lidocaine may be an effective alternative to opioids in the treatment of refractory malignant pain in the pediatric patient with terminal cancer...
  2. ncbi request reprint Transient leukemia in newborns with Down syndrome
    Gita V Massey
    Department of Pediatrics, VCU Health System, Medical College of Virginia, Richmond, Virginia, USA
    Pediatr Blood Cancer 44:29-32. 2005
    ..We summarize here the known clinical, biological, and cytogenetic features of TL associated with DS...
  3. ncbi request reprint A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): Children's Oncology Group (COG) study POG-9481
    Gita V Massey
    Virginia Commonwealth University, Medical College of Virginia, PO Box 980121, Richmond, VA 23298, USA
    Blood 107:4606-13. 2006
    ..Ongoing collaborative clinical studies are needed to determine the optimal role of chemotherapy for infants at risk for increased mortality or disease recurrence and to further the knowledge of the unique biologic features of this TL...
  4. ncbi request reprint Incidence and treatment of potentially lethal diseases in transient leukemia of Down syndrome: Pediatric Oncology Group Study
    Fawaz Al-Kasim
    Division of Hematology Oncology, The Hospital for Sick Children, Toronto, Ontario, Canada
    J Pediatr Hematol Oncol 24:9-13. 2002
    ..In all these patients, the disease resolved. It is concluded that potentially lethal disease is relatively common in TL, and the available evidence suggests that these diseases are responsive to low-dose Ara-C therapy...
  5. doi request reprint Cardiomyopathy in children with Down syndrome treated for acute myeloid leukemia: a report from the Children's Oncology Group Study POG 9421
    MAUREEN M O'BRIEN
    Division of Pediatric Hematology Oncology, Lucile Packard Children s Hospital, Stanford, CA 94304, USA
    J Clin Oncol 26:414-20. 2008
    ..To determine the outcomes, with particular attention to toxicity, of children with Down syndrome (DS) and acute myeloid leukemia (AML) treated on Pediatric Oncology Group (POG) protocol 9421...